A system biology approach reveals cellular pathway differences between follicular thyroid carcinoma and follicular thyroid adenoma

Abstract

Pathogenic mechanisms that underlie malignant follicular thyroid carcinoma (FTC) development are poorly understood. To identify key genes and pathways driving malignant behaviour we employed a system biology-based integrative analyses comparing FTC transcriptomes with a similar but benign lesion, follicular thyroid adenoma (FTA). We identified differentially expressed genes (DEGs) in microarray gene expression datasets (n=52) of FTCs and FTA tissues. Pathway analyses of DEGs using gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) resources revealed significant pathways, and pathway hub genes using protein-protein interactions (PPI). We identified 598 DEGs (relative to FTAs) in FTCs and 12 significant pathways with altered expression in FTC. 10 GO groups were significantly connected with FTC-high expression DEGs and 80 with low-FTC expression. PPI analysis identified 12 potential hub genes based on degree and betweenness centrality. Moreover, 10 transcription factors (TFs) were identified that may underlie DEG expression as well as a number of microRNA (miRNAs). Thus, we identified DEGs, pathways, TFs and miRNAs that reflect molecular mechanisms differing between FTC and benign FTA. These may constitute biomarkers that distinguish these lesions and, given the similarities and common origin of the lesions, they may also be indicators of malignant progression potential.